Interaction Checker

Interaksi Somatropin

Somatropin (Genotropin, Humatrope, Norditropin) memiliki 83 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 23 mayor, 60 moderat, 0 minor, dan 0 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Interaksi dari label

Interaksi mayor (23)

  • Azelastin dan flutikasonantihistaminMayor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (label Somatropin, Interaksi obat)

  • BeklometasonkortikosteroidMayor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (label Somatropin, Interaksi obat)

  • BetametasonkortikosteroidMayor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (label Somatropin, Interaksi obat)

  • BudesonidkortikosteroidMayor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (label Somatropin, Interaksi obat)

  • Budesonid dan formoterolkortikosteroidMayor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (label Somatropin, Interaksi obat)

  • DeflazakortkortikosteroidMayor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (label Somatropin, Interaksi obat)

  • DeksametasonkortikosteroidMayor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (label Somatropin, Interaksi obat)

  • DesonidkortikosteroidMayor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (label Somatropin, Interaksi obat)

  • FludrokortisonkortikosteroidMayor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (label Somatropin, Interaksi obat)

  • FlunisolidkortikosteroidMayor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (label Somatropin, Interaksi obat)

  • FluosinonidkortikosteroidMayor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (label Somatropin, Interaksi obat)

  • FlutikasonkortikosteroidMayor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (label Somatropin, Interaksi obat)

  • Flutikason dan salmeterolkortikosteroidMayor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (label Somatropin, Interaksi obat)

  • HalobetasolkortikosteroidMayor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (label Somatropin, Interaksi obat)

  • HidrokortisonkortikosteroidMayor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (label Somatropin, Interaksi obat)

  • KlobetasolkortikosteroidMayor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (label Somatropin, Interaksi obat)

  • MetilprednisolonkortikosteroidMayor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (label Somatropin, Interaksi obat)

  • MometasonkortikosteroidMayor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (label Somatropin, Interaksi obat)

  • Olopatadin dan mometasonantihistaminMayor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (label Somatropin, Interaksi obat)

  • PrednisolonkortikosteroidMayor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (label Somatropin, Interaksi obat)

  • PrednisonkortikosteroidMayor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (label Somatropin, Interaksi obat)

  • SiklesonidkortikosteroidMayor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (label Somatropin, Interaksi obat)

  • TriamsinolonkortikosteroidMayor

    Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (label Somatropin, Interaksi obat)

Interaksi moderat (60)

  • AkarbosaantidiabetesModerat

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (label Somatropin, Peringatan dan perhatian)

  • Alogliptinpenghambat DPP-4Moderat

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (label Somatropin, Peringatan dan perhatian)

  • Alogliptin dan metforminpenghambat DPP-4Moderat

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (label Somatropin, Peringatan dan perhatian)

  • Beksagliflozinpenghambat SGLT2Moderat

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (label Somatropin, Peringatan dan perhatian)

  • Dapagliflozinpenghambat SGLT2Moderat

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (label Somatropin, Peringatan dan perhatian)

  • Dapagliflozin dan metforminpenghambat SGLT2Moderat

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (label Somatropin, Peringatan dan perhatian)

  • Desogestrel dan etinilestradiolkontrasepsi oralModerat

    Oral Estrogen Clinical Impact: Oral estrogens may reduce the serum IGF-1 response to HUMATROPE. (label Somatropin, Interaksi obat)

  • Drospirenon dan etinilestradiolkontrasepsi oralModerat

    Oral Estrogen Clinical Impact: Oral estrogens may reduce the serum IGF-1 response to HUMATROPE. (label Somatropin, Interaksi obat)

  • Dulaglutidagonis reseptor GLP-1Moderat

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (label Somatropin, Peringatan dan perhatian)

  • Eksenatidagonis reseptor GLP-1Moderat

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (label Somatropin, Peringatan dan perhatian)

  • Empagliflozinpenghambat SGLT2Moderat

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (label Somatropin, Peringatan dan perhatian)

  • Empagliflozin dan metforminpenghambat SGLT2Moderat

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (label Somatropin, Peringatan dan perhatian)

  • EstradiolestrogenModerat

    Oral Estrogen Clinical Impact: Oral estrogens may reduce the serum IGF-1 response to HUMATROPE. (label Somatropin, Interaksi obat)

  • Estradiol dan dienogestkontrasepsi oralModerat

    Oral Estrogen Clinical Impact: Oral estrogens may reduce the serum IGF-1 response to HUMATROPE. (label Somatropin, Interaksi obat)

  • Estradiol dan noretisteronestrogenModerat

    Oral Estrogen Clinical Impact: Oral estrogens may reduce the serum IGF-1 response to HUMATROPE. (label Somatropin, Interaksi obat)

  • Estrogen teresterifikasi dan metiltestosteronestrogenModerat

    Oral Estrogen Clinical Impact: Oral estrogens may reduce the serum IGF-1 response to HUMATROPE. (label Somatropin, Interaksi obat)

  • Estrogen terkonjugasiestrogenModerat

    Oral Estrogen Clinical Impact: Oral estrogens may reduce the serum IGF-1 response to HUMATROPE. (label Somatropin, Interaksi obat)

  • Estrogen terkonjugasi dan bazedoksifenestrogenModerat

    Oral Estrogen Clinical Impact: Oral estrogens may reduce the serum IGF-1 response to HUMATROPE. (label Somatropin, Interaksi obat)

  • Etinodiol diasetat dan etinilestradiolkontrasepsi oralModerat

    Oral Estrogen Clinical Impact: Oral estrogens may reduce the serum IGF-1 response to HUMATROPE. (label Somatropin, Interaksi obat)

  • Etonogestrel dan etinilestradiolestrogenModerat

    Oral Estrogen Clinical Impact: Oral estrogens may reduce the serum IGF-1 response to HUMATROPE. (label Somatropin, Interaksi obat)

  • FulvestrantestrogenModerat

    Oral Estrogen Clinical Impact: Oral estrogens may reduce the serum IGF-1 response to HUMATROPE. (label Somatropin, Interaksi obat)

  • GlibenklamidsulfonilureaModerat

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (label Somatropin, Peringatan dan perhatian)

  • Glibenklamid dan metforminsulfonilureaModerat

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (label Somatropin, Peringatan dan perhatian)

  • GlimepiridsulfonilureaModerat

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (label Somatropin, Peringatan dan perhatian)

  • GlipizidsulfonilureaModerat

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (label Somatropin, Peringatan dan perhatian)

  • Glipizid dan metforminsulfonilureaModerat

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (label Somatropin, Peringatan dan perhatian)

  • Insulin aspartinsulinModerat

    Glucose Intolerance and Diabetes Mellitus: HUMATROPE may decrease insulin sensitivity, particularly at higher doses. (label Somatropin, Peringatan dan perhatian)

  • Insulin degludekinsulinModerat

    Glucose Intolerance and Diabetes Mellitus: HUMATROPE may decrease insulin sensitivity, particularly at higher doses. (label Somatropin, Peringatan dan perhatian)

  • Insulin detemirinsulinModerat

    Glucose Intolerance and Diabetes Mellitus: HUMATROPE may decrease insulin sensitivity, particularly at higher doses. (label Somatropin, Peringatan dan perhatian)

  • Insulin glargininsulinModerat

    Glucose Intolerance and Diabetes Mellitus: HUMATROPE may decrease insulin sensitivity, particularly at higher doses. (label Somatropin, Peringatan dan perhatian)

  • Insulin lisproinsulinModerat

    Glucose Intolerance and Diabetes Mellitus: HUMATROPE may decrease insulin sensitivity, particularly at higher doses. (label Somatropin, Peringatan dan perhatian)

  • Insulin reguler (manusia)insulinModerat

    Glucose Intolerance and Diabetes Mellitus: HUMATROPE may decrease insulin sensitivity, particularly at higher doses. (label Somatropin, Peringatan dan perhatian)

  • Kanagliflozinpenghambat SGLT2Moderat

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (label Somatropin, Peringatan dan perhatian)

  • Levonorgestrel dan etinilestradiolkontrasepsi oralModerat

    Oral Estrogen Clinical Impact: Oral estrogens may reduce the serum IGF-1 response to HUMATROPE. (label Somatropin, Interaksi obat)

  • Levotiroksinhormon tiroidModerat

    Hypothyroidism: Monitor thyroid function periodically as hypothyroidism may occur or worsen after initiation of somatropin. (label Somatropin, Peringatan dan perhatian)

  • Levotiroksin dan liotironinhormon tiroidModerat

    Hypothyroidism: Monitor thyroid function periodically as hypothyroidism may occur or worsen after initiation of somatropin. (label Somatropin, Peringatan dan perhatian)

  • Linagliptinpenghambat DPP-4Moderat

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (label Somatropin, Peringatan dan perhatian)

  • Linagliptin dan metforminpenghambat DPP-4Moderat

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (label Somatropin, Peringatan dan perhatian)

  • Liotironinhormon tiroidModerat

    Hypothyroidism: Monitor thyroid function periodically as hypothyroidism may occur or worsen after initiation of somatropin. (label Somatropin, Peringatan dan perhatian)

  • Liraglutidagonis reseptor GLP-1Moderat

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (label Somatropin, Peringatan dan perhatian)

  • MetforminbiguanidModerat

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (label Somatropin, Peringatan dan perhatian)

  • MiglitolantidiabetesModerat

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (label Somatropin, Peringatan dan perhatian)

  • NateglinidmeglitinidModerat

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (label Somatropin, Peringatan dan perhatian)

  • Norelgestromin dan etinilestradiolestrogenModerat

    Oral Estrogen Clinical Impact: Oral estrogens may reduce the serum IGF-1 response to HUMATROPE. (label Somatropin, Interaksi obat)

  • Noretisteron dan etinilestradiolkontrasepsi oralModerat

    Oral Estrogen Clinical Impact: Oral estrogens may reduce the serum IGF-1 response to HUMATROPE. (label Somatropin, Interaksi obat)

  • Norgestimat dan etinilestradiolkontrasepsi oralModerat

    Oral Estrogen Clinical Impact: Oral estrogens may reduce the serum IGF-1 response to HUMATROPE. (label Somatropin, Interaksi obat)

  • Norgestrel dan etinilestradiolkontrasepsi oralModerat

    Oral Estrogen Clinical Impact: Oral estrogens may reduce the serum IGF-1 response to HUMATROPE. (label Somatropin, Interaksi obat)

  • PioglitazontiazolidindionModerat

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (label Somatropin, Peringatan dan perhatian)

  • Pioglitazon dan glimepiridtiazolidindionModerat

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (label Somatropin, Peringatan dan perhatian)

  • Pioglitazon dan metformintiazolidindionModerat

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (label Somatropin, Peringatan dan perhatian)

  • Propiltiourasilobat antitiroidModerat

    Hypothyroidism: Monitor thyroid function periodically as hypothyroidism may occur or worsen after initiation of somatropin. (label Somatropin, Peringatan dan perhatian)

  • RepaglinidmeglitinidModerat

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (label Somatropin, Peringatan dan perhatian)

  • Saksagliptinpenghambat DPP-4Moderat

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (label Somatropin, Peringatan dan perhatian)

  • Saksagliptin dan metforminpenghambat DPP-4Moderat

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (label Somatropin, Peringatan dan perhatian)

  • Semaglutidagonis reseptor GLP-1Moderat

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (label Somatropin, Peringatan dan perhatian)

  • Sitagliptinpenghambat DPP-4Moderat

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (label Somatropin, Peringatan dan perhatian)

  • Sitagliptin dan metforminpenghambat DPP-4Moderat

    The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (label Somatropin, Peringatan dan perhatian)

  • Teriparatidhormon tiroidModerat

    Hypothyroidism: Monitor thyroid function periodically as hypothyroidism may occur or worsen after initiation of somatropin. (label Somatropin, Peringatan dan perhatian)

  • Tiamazolobat antitiroidModerat

    Hypothyroidism: Monitor thyroid function periodically as hypothyroidism may occur or worsen after initiation of somatropin. (label Somatropin, Peringatan dan perhatian)

  • Tirzepatidagonis reseptor GLP-1Moderat

    Glucose Intolerance and Diabetes Mellitus: HUMATROPE may decrease insulin sensitivity, particularly at higher doses. (label Somatropin, Peringatan dan perhatian)

Periksa Somatropin terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.